
Sutro Biopharma Stock
Develops protein therapeutics by using OCFS protein synthesis technology
Sign up today and learn more about Sutro Biopharma Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Sutro Biopharma Stock
Sutro Biopharma is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease. Sutro is applying its technology to the development of next-generation, non-native protein structures such as antibody fragments, single-chain antibodies, and other proteins with novel scaffolds. We are also working to provide novel functionalities to our core technology with a goal of further improving the therapeutic benefit of the products we make. Sutro Biopharma, Inc. has a 24,000 sq. ft facility located in South San Francisco, California. Our pilot facility houses 15-Liter fermentors, a 200-L fermentor, and related research, development and downstream activities to support the scale-up of protein therapeutic candidates.
Funding History
January 2006 | $1.0M |
---|---|
October 2007 | $305K |
December 2007 | $21.0M |
March 2009 | $15.0M |
November 2010 | $36.5M |
May 2012 | $16.5M |
December 2013 | $26.0M |
July 2018 | $85.4M |
Management
Founder & Director
James R. Swartz
Vice President of Development and Manufacturing
Henry Heinsohn
Vice President of Research
Aaron Sato
Senior Director, Supply Chain and CMC Team Lead
Heidi Hoffmann
Chief Business Officer
Jeremy Bender
Chief Executive Officer, Board of Directors
William J. Newell
Chief Scientific Officer
Trevor Hallam
Chief Financial Officer
Edward Albini
Press
Wall Streets Journal - Jul, 24 2018
Sutro Biopharma Strikes $1.6 Billion Drug-Development Deal With MerckEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase